Shares of Vertex Pharmaceuticals Inc. VRTX shed 3.38% to $434.82 Wednesday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company ...

F.N.B. Corporation announced its Board of Directors declared a quarterly cash dividend of $0.12 per share on its common stock. The dividend is payable on June 15, 2025, to shareholders of record as of ...

Zacks Research bumped up Vertex Pharmaceuticals’ Q1 2027 earnings forecast by a thrilling one cent, now expecting $4.24 per ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

Ratings for Vertex Pharmaceuticals VRTX were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and $535 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks.